Target intelligence / Profile preview

Nicotinic Acetylcholine Receptor (Neuromuscular) (nAChR)

Target
nAChR
Molecular classification
Ligand-gated ion channel, Receptor
01

Overview

Nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels that respond to the neurotransmitter acetylcholine and the exogenous agonist nicotine. They are found in both the central and peripheral nervous systems, as well as in muscle tissue, where they play a critical role at neuromuscular junctions by mediating fast synaptic transmission and triggering muscle contraction. nAChRs are pentameric complexes composed of five subunits arranged around a central pore. In mammals, 17 different subunits have been identified. The muscle-type nAChR at the neuromuscular junction is typically made up of two α1 subunits plus one each of β1, δ, and either γ (fetal form) or ε (adult form). At neuromuscular junctions, activation by acetylcholine leads to opening of a non-selective cation channel allowing Na⁺ influx and K⁺ efflux; this depolarizes the postsynaptic membrane leading to muscle contraction. Dysfunction or autoimmune targeting leads to diseases such as myasthenia gravis. nAChRs are major drug targets for muscle relaxants during surgery and treatment strategies for neurological diseases involving cholinergic dysfunction. Mutations affecting specific nAChR subunit genes can cause inherited disorders like autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE).

Other names
Nicotinic acetylcholine receptorAChRnACh receptor
02

Mechanism of action

Activation by acetylcholine leads to opening of a non-selective cation channel allowing Na⁺ influx and K⁺ efflux; this depolarizes the postsynaptic membrane leading to muscle contraction

03

Biological functions

Synaptic transmissionMuscle contractionSignal transduction
04

Disease associations

Myasthenia gravisAutosomal dominant nocturnal frontal lobe epilepsy (ADNFLE)Neurological diseases involving cholinergic dysfunctionNicotine dependence
05

Safety considerations

Autoimmune targeting in myasthenia gravisSide effects of muscle relaxants
06

Interacting drugs

Acetylcholine

4 more in the full profile.

Beyond the preview

Go deeper on Nicotinic Acetylcholine Receptor (Neuromuscular) (nAChR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nicotinic Acetylcholine Receptor (Neuromuscular) (nAChR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call